Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Executive Summary

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

You may also be interested in...



Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs

Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.

Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs

Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.

Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?

Pfizer and Allergan confirmed they are in friendly merger negotiations. Now the question is if Pfizer can afford to pay for Allergan and will the US government let a pharma giant the size of Pfizer go without a fight.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel